# Thyroid hormone receptor beta signaling is a targetable driver of prostate cancer growth

## TL;DR

Blocking thyroid hormone receptor beta (TRβ) with a drug called NH-3 can slow prostate cancer growth, especially in advanced cases.

## Contribution

The study identifies TRβ as a new target for prostate cancer treatment and shows that NH-3 is effective, even in resistant cancer models.

## Key findings

- NH-3 inhibits prostate cancer cell growth in lab and animal models.
- TRβ signaling is linked to androgen receptor activity in prostate cancer.
- Blocking TRβ with NH-3 is more effective than current treatments like enzalutamide.

## Abstract

Thyroid hormone (TH) signaling plays a major role in the development, energy homeostasis, and metabolism of most tissues. Recent studies have identified THs as drivers of prostate cancer (PCa) development and progression. We reported that the T3-scavenger protein µ-crystallin (CRYM) regulates the development and progression of PCa and that this involved crosstalk with androgen receptor (AR) signaling. However, the mechanisms remain incompletely understood. Here, we explored the role of thyroid hormone receptor β (TRβ), which is the main effector of TH signaling, in the context of PCa. The use of the TRβ-selective antagonist NH-3 inhibited PCa cell proliferation in vitro and reduced tumor size in PCa xenograft models in vivo. Notably, NH-3 was highly effective in the engrafted 22Rv1 cell line, a model for castration-resistant PCa (CRPC). Mechanistic studies revealed that NH-3 downregulates AR and the AR target genes Nkx3.1 and KLK3 (PSA). NH-3 was a more effective anticancer agent than enzalutamide, and their combined use was synergistic. Evidence from human datasets corroborates our findings, whereby elevated TRβ expression and mutations in the TH signaling pathway are associated with the onset of PCa. Collectively, these results establish TRβ as a mediator of tumorigenesis in PCa and identify NH-3 as a promising therapeutic agent for targeting AR signaling, particularly in CRPC.

The online version contains supplementary material available at 10.1186/s12943-025-02451-2.